Guggenheim Capital’s ADMA Biologics ADMA Stock Holding History

Guggenheim Capital’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.02M	Buy	122,263 +37,491	+44%	+$342K	0.01%	1013
2026 Q1	$764K	Sell	84,772 -13,929	-14%	-$220K	0.01%	1072
2025 Q4	$1.8M	Buy	98,701 +29,691	+43%	+$500K	0.01%	699
2025 Q3	$1.01M	Buy	69,010 +7,478	+12%	+$128K	0.01%	915
2025 Q2	$1.12M	Sell	61,532 -1,959	-3%	-$39.9K	0.01%	845
2025 Q1	$1.26M	Sell	63,491 -4,287	-6%	-$74.1K	0.01%	794
2024 Q4	$1.16M	Buy	67,778 +57,000	+529%	+$1.07M	0.01%	843
2024 Q3	$215K	Buy	+10,778	New	+$168K	﹤0.01%	1745
2016 Q3	–	Sell	-29,747	Closed	-$177K	–	2883
2016 Q2	$177K	Buy	29,747 +7,929	+36%	+$55.5K	﹤0.01%	2684
2016 Q1	$177K	Buy	21,818 +4,286	+24%	+$24.5K	﹤0.01%	2701
2015 Q4	$142K	Sell	17,532 -787	-4%	-$7.08K	﹤0.01%	2811
2015 Q3	$153K	Buy	+18,319	New	+$169K	﹤0.01%	2769

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Guggenheim Capital's ADMA Position: Q2 2026 in Review

Guggenheim Capital increased its ADMA Biologics (ADMA) stake by 44% in Q2 2026, buying an estimated $342K and bringing the position to 122,263 shares worth $1.02M. The position accounts for 0.01% of the portfolio, ranked #1013.

Guggenheim Capital first reported a position in ADMA in Q3 2015 and has held it in 12 quarters since. The position peaked at $1.8M in Q4 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Guggenheim Capital held 122,263 shares of ADMA Biologics worth $1.02M as of Q2 2026.
Guggenheim Capital bought 37,491 ADMA Biologics shares in Q2 2026, an estimated $342K.
ADMA Biologics made up 0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1013 holding.
Guggenheim Capital first reported a position in ADMA Biologics in Q3 2015 and has held it in 12 quarters since.
Guggenheim Capital's ADMA Biologics position peaked at $1.8M in Q4 2025.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.